Martin Shkreli, the former pharmaceutical CEO who acquired the moniker “Pharma Bro” after hiking the price of a life-saving HIV medicine by more than 5,000%, is making headlines again. This time, it’s for allegedly attempting to launch another pharmaceutical firm after being barred from the industry for life in a separate trial over the Daraprim debacle.
For breaking the order, the Federal Trade Commission (FTC) has asked a federal judge to punish Shkreli in contempt of court. U.S. District Court Judge Denise Cote stated in a 135-page order in the winter of 2022 that “Shkreli’s egregious, purposeful, persistent, long-running, and ultimately hazardous unlawful conduct merits enforcement of an injunction of this extent.”
